AUTEL
Autel is today announcing the launch of an innovative electric vehicle DC charger, the MaxiCharger DC Compact, providing up to 40kW of DC power for the U.S. version and 47kW of power for the European version. The MaxiCharger DC Compact comes with two charging cables, allowing two vehicles to charge simultaneously with dynamic power distribution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005624/en/
The MaxiCharger DC Compact comes with options like a credit card reader and a pedestal. (Photo: Business Wire)
The MaxiCharger DC Compact is sleek and compact with a 21.5-inch LCD touchscreen for user-friendly interaction and advertising capability. It can be hung on a wall, placed on a pedestal, or set on wheels for ultimate portability. The MaxiCharger DC Compact is perfect for businesses wanting to provide their customers with a quick top-up charge option without breaking the bank on a DC Fast charger. It is also an excellent option for commercial fleets that need a slower DC charge for their fleet vehicles to charge overnight.
“This is an exciting launch for Autel as we establish ourselves as the worldwide leader in electric vehicle charging,” said Kelvin Cao, Vice President of Global Marketing at Autel. “The MaxiCharger DC Compact is small in size but a powerful addition to our growing portfolio of EV chargers, and a great fit for businesses needing an affordable, yet fast EV charger.”
Elevated Efficiency with Dual Ports
The MaxiCharger DC Compact is designed to increase charging efficiency, providing up to 47kW of power with dual-ports. It can charge 2 vehicles simultaneously, sharing power dynamically between the two vehicles. A 30 minute charge equates to about 130 km of range, saving on charging time.
Smart Advertising and Communication Platform
Powered by the smart operating system, Android 10, with a user-friendly 21.5-inch LCD touchscreen and enhanced advertising placement capability, the MaxiCharger DC Compact communicates with, engages and attracts customers, generating new revenue streams.
Compatibility
The MaxiCharger DC Compact is OCPP1.6 capable. It is compatible with CCS1, CCS2 and CHAdeMO charging cables, depending on operator and regional needs. With the Autel Charge app, RFID cards, and credit card capability, the MaxiCharger DC Compact offers convenient ways for end users to pay for and begin their charging sessions. It offers 4G, Wi-Fi, and ethernet connectivity options and supports regular over-the-air software updates with an internet connection.
Cloud Platform
The MaxiCharger DC Compact is powered on the backend using Autel’s smart charge cloud platform. The cloud platform helps charge point operators view, monitor, and analyze charger data in real-time. Operators can also view revenue and user data, and set advertisements all from the cloud platform. Autel’s cloud management platform allows all operators to efficiently and conveniently manage their chargers in one easy-to-use interface.
Become a Dealer
If you are interested in becoming a dealer for the MaxiCharger DC Compact and for all of the MaxiCharger series of EV chargers, head over to the Autel website and fill out our dealer form. If you are interested in purchasing a MaxiCharger DC Compact, contact your local Autel sales representative or contact us below.
About Autel
Autel designs, engineers, and manufactures some of the most advanced products for residential and commercial users, offering hardware, software, apps, and cloud-based solutions to cover almost every use case and application.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005624/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom